Logotipo del repositorio
Comunidades y Colecciones
Estadísticas
¿Nuevo Usuario? Pulse aquí para registrarse¿Has olvidado tu contraseña?
  1. Inicio
  2. Producción Científica UPeU
  3. Publicaciones
  4. P-997. Successful Implementation of an Infectious Disease-Led Non-Restrictive Antimicrobial Stewardship Program in a Peruvian Hospital

P-997. Successful Implementation of an Infectious Disease-Led Non-Restrictive Antimicrobial Stewardship Program in a Peruvian Hospital

Author(s)
Xossé Carreras
Andrea Sofia Salcedo
Sara Muñoz
N García Díaz
Jorge Salinas
Marisa Holubar
Date Issued
1 de enero de 2026
Type
Article
Volume
13
Issue
Supplement_1
DOI
10.1093/ofid/ofaf695.1196
Abstract
Abstract Background Peru reports high carbapenem and vancomycin usage with concerning resistance rates, including 60.6% third-generation cephalosporin resistance in E.coli bloodstream infections. National legislation requires antimicrobial stewardship programs (ASPs) in secondary and tertiary facilities. Methods We implemented an infectious disease physician-led ASP at a 107-bed Peruvian hospital and report 12-month outcomes. Implementation phases included education and guideline development, prospective audit and feedback without restrictions, and data collection. The ASP targeted meropenem, vancomycin, and linezolid in medicine and ICU wards. Medical students conducted chart reviews with recommendations communicated to physicians. Results We audited 191 records of predominantly elderly patients (median 78 years), with meropenem most prescribed (89.4%). Guideline adherence was 84.7%. Common recommendations included limiting duration (39.2%), adjusting based on cultures (31.7%), and de-escalation (18.5%)(Table1). Implementation rate was 78.8%. In medicine, consumption decreased during intervention: meropenem by 57.1% (10.5 to 4.5 DDD/100 patient-days), vancomycin by 76.7% (1.8 to 0.42), and linezolid by 50% (1.0 to 0.5)(Figure1). In ICU, reductions were 48.6% for meropenem, 50% for vancomycin, with continued post-intervention decreases(Figure2). Challenges included physician resistance, risk-averse prescribing, and suboptimal diagnostics. Conclusion ASPs can be effectively implemented in resource-limited settings through leadership, education, and non-restrictive approaches. Success factors included collaborative methods, multimodal communication, continuous education, and transparent reporting. The post-prescription audit and feedback model maintained physician autonomy while reducing broad-spectrum antibiotic use. Disclosures All Authors: No reported disclosures
Subjects

Medicine

Meropenem

Linezolid

Antimicrobial steward...

Guideline

Vancomycin

Intensive care medici...

Antibiotic resistance...

Infection control

Carbapenem

Audit

Drug Utilization Revi...

Medical record

Drug resistance

Stewardship (theology...

Antibacterial agent

MEDLINE

Carbapenem-resistant ...

Family medicine

Antibiotics

Emergency medicine

Medical prescription

Medical emergency

Infectious disease (m...

Acinetobacter baumann...

Cephalosporin

Pediatric Infectious ...

Antibiotic Stewardshi...

Meropenem

Linezolid

Antimicrobial steward...

Guideline

Vancomycin

Antibiotic resistance...

Infection control

Carbapenem

Audit

Life Sciences Immunol...

Life Sciences Biochem...

Life Sciences Biochem...

Metrics
Get Involved!
  • Source Code
  • Documentation
  • Slack Channel
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your Institution's web identity.

Need professional help?

The original creators of DSpace-CRIS at 4Science can take your project to the next level, get in touch!

Desarrollado con Software DSpace-CRIS - Extensión mantenida y optimizada por 4Science

  • Accessibility settings
  • Política de privacidad
  • Acuerdo de usuario final
  • Enviar Sugerencias
InvestigadoresUnidades OrganizativasProyectosFinanciamientosProducción CientíficaPatentes
InvestigadoresUnidades OrganizativasProyectosFinanciamientosProducción CientíficaPatentes